First, the xenograft model used in this study did not fully recapitulate the complex tumor microenvironment and immune system of human sarcomas, and thus the findings, including the retention of LAT1 expression after 211At-AAMT treatment, may not be entirely extrapolated to clinical settings. The gene discussed is SLC7A5; the disease is sarcoma.